Akari Therapeutics (AKTX) Proxy Filing summary

Executive summary

• A general meeting is scheduled for March 2, 2026, to vote on five resolutions related to the exercisability of various warrants and the issuance of underlying shares, all in compliance with Nasdaq Listing Rules 5635(c) and 5635(d).

• The meeting will address warrants issued in recent registered direct offerings, private placements, and note exchanges, with potential proceeds of up to $8.9 million if all warrants are exercised for cash.

• The board unanimously recommends voting in favor of all resolutions, citing their importance for the company's success and compliance.

Voting matters and shareholder proposals

• Shareholders will vote on five resolutions approving the exercisability and issuance of shares underlying Series G, Pre-Funded, Note Exchange, and Placement Agent Warrants.

• Approval is required to comply with Nasdaq rules due to the size and pricing of the offerings and the involvement of directors and officers.

• Failure to approve would prevent warrant exercise, potentially causing additional costs and repeated meetings.

• Only the five specified resolutions will be considered; no other business will be conducted.

Board of directors and corporate governance

• The board has reviewed and unanimously approved all proposals, recommending a "FOR" vote on each.

• The board's recommendation is based on the belief that the proposals are in the best interests of shareholders.